A live archive of receipt-bound excerpts from company earnings calls. No generated thesis, no recommendation — just the recorded language, its source coordinates, and a direct path into the ticker dossier or live Terminal.来自公司财报电话会的可追溯摘录档案。没有生成式投资结论，也没有推荐——只有原始表述、来源坐标，以及进入个股档案或实时终端的直接入口。
Start free in Terminal免费开始使用终端50 verified call records份已核验电话会记录 · 600 exact facts条精确事实 · 2026-09-07 → 2026-09-13
Browse the full archive page by page. Search on this page by ticker, period, category, or speaker; every card preview is a verbatim call excerpt.分页浏览完整档案。在本页按代码、期间、分类或发言人搜索；每张卡片预览均为电话会原文摘录。
Showing records 1633–1728 of 5581.显示第 1633–1728 条，共 5581 条。
“In terms of cash flow, net cash in operating activities for the second quarter of 2026 used was approximately $5.1 million, that compares with the cash usage of $2.0 million in the second quarter of 2025 and a usage of $4.2 million in the first quarter of 2026.”
“Do you think it's like the 2027 revenue growth is largely predicated on what Cylinder has sold year-to-date, or is that something you feel like you can actually add to your customer base and cross-sell through in that fourth quarter, and then obviously as we go through into 2028 and beyond?”
“We have also declared a dividend of $0.60 per share this quarter, which keeps us on track for the 11% increase over last fiscal year, equating to the targeted $2.40 per share for fiscal year 2027.”
“Our increased midpoint of $1.695 billion now represents 9% growth over last year, which again, is in line with our long-term growth targets.”
“We expect the adjusted gross margin as a percentage of revenues before reimbursements to be approximately 46%-47%.”
“At a business level, Zoro saw strong growth from its core B2B customers, along with higher customer retention rates as our marketing program, both targeted and efficiency, continued to improve.”
“Adjusted EBITDA grew 54% year-over-year to $168 million, more than twice our revenue growth rate, with margin expanding to 16.9% of revenue from 13.3%.”
“I've had 37 years of TradFi experience, so those of you who follow me know I know a lot of people in the space, and I think the backlog for tokenization for us is going to really lead to gross margin, and I'm very, very excited about financial services.”
“Altogether, we expect positive pricing momentum to favorably impact 2026 full-year sales and EBITDA by approximately $60 million, with fourth quarter benefiting more than third quarter.”
“Excluding approximately $9.15 per share relating to the acquired IPR&D expense and full-year financing costs associated with the Arcellx, Tubulis, and Ouro Medicines transactions, as well as non-recurring other revenue, our full-year non-GAAP diluted EPS would be $8.50-$8.85, raised $0.05 on the bottom end from our May illustrative guidance due to higher base sales, partially offset by lower Veklury sales.”
“As a reminder, gross margin during the second quarter of 2025 was a record 37.1%, which included approximately 150 basis points of FIFO-related timing benefits associated with price increases taken upon the imposition of increased tariffs in April 2025.”
“About 78% of our new origination volume in the third fiscal quarter supported M&A-driven transactions such as LBOs and add-on acquisitions, which builds on the momentum we saw last quarter and highlights our ability to benefit from the early signs of a more active and M&A-driven market environment.”
“The sales volumes of our 2025 and 2026 restaurant classes continue to outperform both the comp restaurant base and, importantly, their underwriting targets.”
“Our full year 2026 revenue estimates include a $2 million FX headwind.”
“Based on our first half performance and continued momentum across submissions and funded production, we are reaffirming our full year guidance of funded volume between $2.8 billion and $3.1 billion and adjusted EPS between $4.50 and $5 per share.”
“For the binders, yes, we did see in the first half around the EUR 70 million positivity year-over-year, and we expect this to turn into a headwind of around EUR 120 million year-over-year in the second half, resulting in the EUR 50 million for the full year.”
“Second, because these streams carry lower growth margins than our blended average, full year growth margin decline would be higher than the range we previously discussed, closer to 350 basis points on a reported basis and closer to 200 if normalized for the current payment ramps in healthcare and B2B.”
“This is a 225 basis point reduction compared to our prior outlook of 5.5% growth and includes a 120 basis point impact from lower professional services, with the remainder coming from slower recurring revenue growth.”
“I think you conservatively use around $65, but the question is more just how much do you think some of the operational improvements and resource expansion initiatives you've achieved can contribute to a higher NAV plus just more volumes or growth?”
“Adjusted EBITDA margin contracted approximately 200 basis points to 38.3%, also reflecting the impact of the discount, partially offset by the non-recurrence of product-related expenses recorded in the prior year.”
“This is a good segue into slide 12, which shows a total pre-order backlog of approximately 2,700 aircraft valued at about $13.5 billion at list price, including the two new LOIs signed this quarter and announced at the Farnborough Airshow.”
“Growth in Materials Solutions accelerated from the first quarter, and we expect the MS segment to deliver double-digit year-over-year growth in the second half of 2026, benefiting from increased demand across deposition, CMP, etch, and implant materials product lines.”
“We expect fourth quarter gross margin to be north of 40%, and we expect 25% adjusted EPS growth at the midpoint in Q4.”
“As a result of the strong financial performance in the first half of the year, we are raising our full-year revenue guidance to a range of $790 million to $820 million, from $755 million to $785 million, and our adjusted EBITDA guidance to $565 million to $585 million, from $545 million to $565 million.”
“We are raising full year growth guidance for Test & Measurement, now 14%, and Control Systems & Software, now 3.5%, including approximately three points of headwind from software renewals.”
“Gross margin as a percent of revenue was 61.6%, reflecting the continued mix shift toward our usage-based offerings, which in aggregate carry a lower margin profile but can add meaningful gross and operating profit dollars as the business scales.”
“Second, tax-related factors impacted results by COP 1.2 trillion, mainly explained by the income tax surcharge, which increased from 0% in 2025 to 10% in 2026, in line with the Brent price outlook for this year, as well as the recognition of the new wealth tax.”
“Patient care cost per treatment declined approximately $3 sequentially as a result of operating leverage on labor and other fixed costs, driven by increased treatment volume in Q2 and a decline in phosphate binder costs, offset by higher benefit costs.”
“We are also reaffirming our long-term earnings per share growth rate of 5%-7% through 2030, and we are more confident than ever that we will deliver in the top half of the range beginning in 2028, when we expect to see accelerated growth from the economic development projects we have secured under ESAs.”
“On the margin front, we're now targeting a full year adjusted operating income margin of approximately 15.5%-16.5%, up from our previous expectations of 15%-16%.”
“We now expect revenue growth of approximately 30% for the full year 2026, and to reach at least 35% growth by Q4 of 2026.”
“As production volumes scale and we continue to optimize our manufacturing operations, we expect parts manufacturing to become an increasingly meaningful contributor to both revenue and profitability.”
“Therefore, for the third quarter 2026, we estimate net sales of $1.835 billion, Operating EBITDA of $448 million, and Operating EBITDA margins of 24.4%, including a 50 basis point headwind from oil and gas inflation.”
“As a result, our backlog stands at $4.6 billion with a 4.7 average charter duration, while contract coverage is already at 100% for this year, 93% for 2027, 79% for 2028, and 61% for 2029.”
“Year-to-date organic revenue growth of 11% is in line with our guidance of delivering double-digit organic growth for the year.”
“For 2026, we expect base revenue of $3.5 billion-$3.7 billion and base gross profit of $270 million-$290 million.”
“The strong environment in the T&D end markets and overall strength across both of our segments, we are also raising both the bottom and top ends of our adjusted EBITDA guidance and now project a range of $437.5 million-$455 million, resulting in year-over-year growth of 14%-19%.”
“Going forward, we expect to continue to add resources to our team while maintaining operating leverage in the 1.4%-1.5% range.”
“In particular, Minneapolis delivered blended rent growth of 3.4%, with retention at 65%, evidence that the market has absorbed the elevated supply that had challenged many markets across the country.”
“That operating momentum supports an enhanced outlook both in 2026 and beyond and gives us a greater opportunity to create value through free cash flow and disciplined capital allocation.”
“As we execute these priorities, we expect to deliver a more compelling experience for our customers while positioning the business for stronger long-term growth.”
“This represents a contraction of approximately 390 basis points year-over-year, resulting from the gross profit margin impacts I just described, as well as the headwinds from our current capacity and fixed cost structure built against a pre-incident demand curve.”
“Assuming current 2026 consensus adjusted EBITDA estimates in our Q2 ending cash balance of $694 million, which would be conservative as we expect to generate free cash flow in the second half of the year.”
“For components, we expect 2026 revenues to be up 8%-13%, up from our prior outlook of growth of 7.5% at the midpoint, due to stronger demand for trucks in North America, stronger demand in on and off highway markets in China.”
“Beyond those initial campuses, our pipeline keeps expanding with approximately 4.4 GW of expected future developments, giving us years of visibility into growth well beyond what's already under contract.”
“We continue to expect 2026 revenue growth in the range of 0% to 4%, which translates into full-year revenue of $367 million to $382 million on a comparable continuing operations basis.”
“Cost of sales per unit case increased by 0.6%, lower than our full year guidance of around 1.5%, and this largely reflects both a higher half one comparable of 3.6% last year and with much of the absorption of the ongoing uncertain situation in the Middle East, still to land in half two.”
“Given the year-to-date performance and our expectations for the fourth quarter, we are tightening our fiscal 2026 adjusted earnings per share guidance range from $6-$6.50 per share to $6.15-$6.45 per share.”
“We are increasing our full-year 2026 sales and revenues expectations to mid to high teens growth based on the healthy demand we are seeing across all three of our primary segments.”
“This increase represents the following: $21 million of the increase is related to the flow-through of the non-tariff Q2 EBITDA exceed, an additional $3 million from the flow-through of our improved net sales outlook and a slightly improved gross margin outlook.”
“On the origination side, consumer loan assignment unit volume declined 1% year-on-year.”
“Advertising revenue decreased by $5.3 million for the three months ended June 30, 2026.”
“We also have increasing visibility over the long term given the accelerating hyperscaler CapEx spend, which is expected to exceed $800 billion this year just from the top five alone, nearly double last year and a fraction of the $3 trillion we expect to see over the next five years.”
“Higher oil pricing and production helped offset the impact of lower gas volumes and contributed to strong cash flow generation during the period.”
“Non-cash service revenue amortization is estimated to have a $0.94 impact on full-year adjusted EPS, which more than covers the current dividend run rate.”
“I think, Tycho, to your operating margin question, if you even look at our slide 15, if we haven't been clear enough, our guidance continues to be based on an operating margin up 250 to 300 basis points reported, including a 50 basis points headwind, and detailed a little bit on our slide 15 on the outlook.”
“Based on our first half performance and continued execution against our full year plan, we are maintaining our 2026 outlook of at least 8% revenue growth or approximately $430 million and at least 35% Adjusted EBITDA growth or approximately $29 million.”
“Turning to our 2026 outlook, we now expect full-year net sales of $2.335 billion-$2.375 billion, which represents growth of 1%-3% versus our prior guidance of flat to 2% growth.”
“Our guidance is calling for another 5%-7% organic growth with an additional point from acquisitions.”
“I would just remind you that over six years now, we've added 4% uplift to the group earnings on average capital employed from trading, and that has been through benign and volatile years.”
“In terms of revenue phasing through the rest of the year, we continue to expect the majority of our 2026 revenues to be realized in the second half of the year, specifically in the third quarter when we expect to recognize the EUR 613 million BMS collaboration payment.”
“Total revenue was $187.8 million, up 9.2%, with subscription revenue growth of 9% and professional services revenue growth of 11%, reflecting strength in go live activity and early AI deployment with customers.”
“Sequentially, our plywood sales volumes were down 1% from first quarter 2026 as we diverted more veneer to EWP production to meet stronger than anticipated demand across our EWP product lines.”
“We expect revenue to be in the $505 million-$525 million range, we expect margins to improve materially from what we just reported to close to 30%, potentially touching 30%.”
“What I will say, and I reiterate, is we grew 4-plus% in Q2 on the back of 4-plus% growth last year for the full year and 4% in the Q2 last year.”
“Revenue in the second quarter was $158,000, consisting of fees for wafer deliveries to customers, primarily to our large IDM customer.”
“Given our growth outlook, sustained improvement in gross margins, and ongoing operating discipline, we are raising our adjusted EBITDA guidance to approximately $140 million, representing a 16% margin, up from our prior outlook of $134 million.”
“The increase year-over-year was primarily attributed to a $32 million increase in candidate costs, reflecting continued progression of our pipeline through clinical development, including the phase III registration of program for plozasiran in SHTG, as well as increased manufacturing and clinical supply activity.”
“We continue to maintain our cash runway guidance into the second half of 2028, and in doing so, we will be able to fund operations through key data milestones over the coming months and continue to support our highly differentiated pipeline programs that have the potential to meaningfully improve patients' lives.”
“We expect adjusted EBITDA in the range of $2.31 billion to $2.37 billion and an EBITDA margin of 18.4% at the midpoint, reflecting the impact of lower revenue growth, which is partially offset by performance.”
“Growth in international ODS continues to be a bright spot as higher device volumes combined with higher revenue per device or RPD drove nearly 80% year-over-year growth.”
“Importantly, forward earnings indicators, including our capital formation and origination pipelines, committed capital not yet earning management fees, and signed originations with future syndication fees, are all very strong and continue to build, providing confidence that we'll hit our 20% plus FRE growth outlook for the year, as well as establishing embedded momentum for 2027.”
“We have increased our fiscal 2026 operating margin target now at a range of 48%-49%, while maintaining an expected tax rate of 21.5%.”
“We expect increased demand later in the year for our ownership due to the geographic dispersion of harvested bushels for both hard and soft wheat.”
“We now expect full year 2026 revenue in the range of $200 million-$205 million, raising the low end of our previously communicated range of $195 million-$205 million.”
“For the full year, we expect capital expenditures of approximately $160 million or about 2% of sales.”
“In server CPUs, with very strong customer demand and improved supply, we now expect server revenue to grow more than 80% year-over-year in the second half of 2026 and more than 70% for the full year 2027 off a much higher base.”
“As previously indicated, we expect there to be significant earnings growth in 2027 as the positive impact and the lease off for PENN 1, PENN 2, and our other vacancies continues to take effect, as well as the positive impact of the recent acquisition of Park Avenue Plaza.”
“We delivered $471 million of recurring revenue in the second quarter, a decrease of 4% compared to the second quarter of 2025, reflecting the impact of lower than desired commercial execution in prior years.”
“In looking ahead, we expect unit revenue growth to be in line with the second quarter's 24.6% increase for the third quarter.”
“The target is 15% adjusted operating income margins and 18% adjusted EBITDA margins.”
“Scorpio X-Series is in volume production, and we expect our Scorpio family to become our largest product category by revenue in Q3, a significant milestone in our evolution as a company.”
“Investor demand for retail real estate remains strong as well, with sales volume up 26% year-over-year and cap rates stabilizing after peaking in 2025.”
“We expect Adjusted EBITDA margin of approximately 17.9%, and we expect free cash flow to be approximately $50 million.”
“Starting with revenue, we generated $1.4 billion in the second quarter, up 11% year-over-year at the high end of our guidance range, despite continued pressures in the macroeconomic environment.”
“However, based on recent customer conversations, we expect activity levels to begin ramping moderately in Q4 in a counterseasonal way as customers look to hit 2027 running.”
“Growth was bolstered by higher volume trends with an increase of 2.2% in same store hours per business day within our target range of 2%-2.5%.”
“For my follow-up, I guess it's good to see your commitment to your 10% operating margin target, you're currently at low to mid-single digits due to product mix headwinds in addition to component and freight cost headwinds.”
“To summarize, in AS&O, our team executed well in a complex and volatile environment, strategically leveraging ADM's global asset footprint to drive margin and volume uplift in Ag Services, capture strong crush margins in a constructive biofuels environment, and deliver nearly 5% crush volume growth year-over-year.”
“Turning to our CECL reserve, the total CECL reserve increased marginally to $139 million as of June 30th, 2026, an increase of approximately $900,000 from the CECL reserve as of March 31st, 2026.”
“Customer engagement continues to ramp, and the property delivered its highest quarterly gross profit since we acquired it, which represents 33% growth compared to the second quarter of last year.”
“For NUPLAZID, we expect stronger year-over-year growth in Q4 relative to Q3 due to the greater impact of the expanded field force expected later in the year.”
“We continue to expect exome and genome volume growth of at least 30%, exome and genome revenue growth of at least 20%, gross margin of approximately 70%, and to be profitable for the full year.”
“With more than $8 billion in bids submitted that incorporate these solutions, our focus remains on margin-accretive opportunities that further enhance the quality of our backlog.”
“As our new products, particularly CASGEVY, increase in revenue contribution with higher cost of goods sold than our small molecule CF products, we continue to expect full year gross margin of just under 86%, roughly in line with this quarter's result.”
“Turning to guidance, given the performance of the business in the second quarter and the ongoing impact of the cost actions, we expect third quarter revenue of $208 million-$211 million, and third quarter adjusted EBITDA of $55 million-$57 million.”
Try a ticker, period, category, or a call speaker.请尝试代码、期间、分类或电话会发言人。
This is a transcript-only, historically incomplete publication. Releases, filings, slides, consensus and price reaction are visibly marked as not joined; lower-evidence packets remain held instead of being inferred.这是仅基于电话会文本且历史覆盖尚不完整的发布。新闻稿、披露文件、演示材料、一致预期和股价反应均明确标注为未接入；证据不足的数据包会被暂缓，而非由推断补齐。